Insulet (Nasdaq:PODD) announced today that it is rolling out new algorithm enhancements for its Omnipod 5 automated insulin delivery system. The company also expanded its compatibility with Abbott sensors, adding the option of pairing Omnipod 5 with FreeStyle Libre 3 Plus. Acton, Massachusetts-based Insulet won FDA clearance for its algorithm enhancements in December 2025. The […]
Drug-Device Combinations
MiniMed adds Abbott dual glucose-ketone sensor to portfolio, posts Q4 sales beat
MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio. The company also announced fourth-quarter earnings results in tandem with the new Abbott integration. MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by […]
MyLife integrates MyLoop automated insulin pump with Dexcom G7
MyLife Diabetes Care, CamDiab and Dexcom today announced the integration of the G7 continuous glucose monitor (CGM) into the MyLoop system. MyLoop (previously MyLife Loop), an automated insulin delivery (AID) system, is powered by the CamAPS FX app. The system already integrated with the previous-generation Dexcom G6, as well as Abbott’s FreeStyle Libre 3 Plus. […]
Beta Bionics makes near-real-time, real-world bionic pancreas data publicly available
Beta Bionics (Nasdaq:BBNX) today announced the public availability of near-real-time, real-world iLet Bionic Pancreas data. Irvine, California-based Beta Bionics said its dashboard publishes outcomes for 100% of iLet patients who meet two simple, pre-stated criteria (a provider-reported baseline HbA1c and at least two weeks of data uploaded to the cloud), with no exclusions applied. According […]
MyLife takes on manufacturing responsibility for insulin pumps
MyLife Diabetes Care today announced its next steps as an independent diabetes care technology company. Burgdorf, Switzerland-based MyLife says it has now become the legal manufacturer for MyLife products, as of today, June 1, 2026. It plans to introduce products under the new legal manufacturer to the market in a step-by-step process beginning July 1, […]
Ascensia launches new insulin pen needles
Ascensia Diabetes Care, a PHC Holdings subsidiary, today announced the launch of its Contour Comfort pen needles. The Basel, Switzerland-based company said the launch further strengthens its Contour portfolio with a solution that improves the everyday injection experience. It marks the company’s entry into the pen needle category. Ascensia designed Contour Comfort pen needles to […]
Court overturns $60M verdict for Insulet in EOFlow trade secret battle
The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., has sided with EOFlow in its patent spat with Insulet (Nasdaq:PODD). In its decision, the court overturned a verdict from 2024 that ordered EOFlow to pay nearly $60 million to Insulet. A jury found that EOFlow and several other defendants misappropriated Insulet’s trade secrets […]
MannKind wins FDA approval for inhaled insulin for children with type 1, type 2 diabetes
MannKind (Nasdaq:MNKD) announced today that it received FDA approval for its Afrezza inhaled insulin powder for children. FDA approval covers use in children and adolescents aged 6 and older with type 1 and type 2 diabetes. Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler […]
Medtrum data highlights time in range with automated insulin delivery system
Medtrum said that a study of its automated insulin delivery (AID) technology demonstrated increased time in range for people with diabetes. In 20 adults with type 1 diabetes, investigators evaluated the performance of the Medtrum A8 TouchCare in AID mode over three months. Findings included more time in range (70-180 mg/dL), increasing from 59.08% to […]
ViCentra CEO explains how Kaleido can compete with ‘handbrake off,’ increased growth, scale
Since ViCentra closed an $85 million funding round in September 2025, the milestones have continued to stack up. The Dutch automated insulin delivery system developer added a a $13 million extension to that Series D round in January. CEO Tom Arnold outlined the company’s plans for the cash infusion last year, including scaling manufacturing. Today, […]
